Svein Lien appointed ceo of Biotec Pharmacon

Lien has a financial background and extensive experience at technology and diagnostics businesses

Svein Lien has become chief executive of Norwegian pharmaceutical firm Biotec Pharmacon following the resignation of Lars Viksmoen.

Lien has a financial background and extensive experience at technology and diagnostics businesses, most recently as chief executive of Axis-Shield, a diagnostic company listed in London and Oslo.

Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to two core business areas: pharmaceutical development and marine biochemicals.

Pharmaceutical development is in the research and development phase, while Biotec Marine Biochemicals specialises in cold-adapted marine enzymes for the molecular biology and diagnostics markets.

You may also like

Ingredients

ArcticZymes receives research grant of US$1.3m

To develop new enzymes for research and diagnostics
Manufacturing
The 7 most common process development mistakes

The 7 most common process development mistakes

At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
Manufacturing
What are injectable hydrogel microspheres?

What are injectable hydrogel microspheres?

The demand for longer-lasting therapies is accelerating innovation in injectable drug delivery, driven by the need to maintain stable therapeutic levels while minimising repeated administration
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
Regulatory
What is ISO/IEC 17025 and why it matters for calibration

What is ISO/IEC 17025 and why it matters for calibration

As regulatory expectations continue to increase, particularly around data integrity and traceability, the question becomes less about collecting data, and more about trusting it
Subscribe now